Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference

FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.

GlobeNewsWire • Feb 18, 2026

Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026.

GlobeNewsWire • Feb 12, 2026

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

Company to present at the 44th Annual JP Morgan Healthcare Conference Company to present at the 44th Annual JP Morgan Healthcare Conference

GlobeNewsWire • Jan 12, 2026

Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth

Cytek Biosciences offers a full-spectrum cytometry platform. This means they provide instruments, reagents, services, and cloud software. Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance tier.

Seeking Alpha • Nov 20, 2025

TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026

FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME's 2026 list of America's Growth Leaders.

GlobeNewsWire • Nov 12, 2025

Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards.

GlobeNewsWire • Nov 6, 2025

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

GlobeNewsWire • Nov 6, 2025

Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript

Cytek Biosciences, Inc. ( CTKB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Goodson Wenbin Jiang - President, CEO & Chairman of the Board William McCombe - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Brendan Smith - TD Cowen, Research Division Harrison Parsons - Stephens Inc., Research Division Noah Lewis - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, everyone, and thank you for standing by. My name is Arjarie, and I will be your conference operator today.

Seeking Alpha • Nov 6, 2025

Cytek Biosciences Reports Third Quarter 2025 Financial Results

FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025.

GlobeNewsWire • Nov 5, 2025